PIDOTIMOD

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H12N2O4S
Molecular Weight	244.268
Optical Activity	( - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)[C@@H]1CSCN1C(=O)[C@@H]2CCC(=O)N2

InChI

InChIKey=UUTKICFRNVKFRG-WDSKDSINSA-N

InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H12N2O4S
Molecular Weight	244.268
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.thepharmaletter.com/article/focus-on-pidotimod-a-new-biological-response-modifier
Curator's Comment: Description was created based on several sources, including http://www.mims.com/india/drug/info/pidotimod?mtype=generic http://flipper.diff.org/app/pathways/3840

Pidotimod is a synthetic dipeptide with immunomodulatory properties. An immunostimulant used in patients with cell-mediated immunodepression during resp and urinary tract infections. In vitro and in vivo laboratory studies show that treatment with pidotimod causes a significant induction of macrophage and neutrophil polymorphonuclear activity, which is characterized by an increase in spontaneous chemotaxis, superoxide anion production and phagocytosis. Several placebo-controlled trials of the drug have been carried out in various indications such as recurrent respiratory, pharyngotonsillar and urinary infections in children, and in adults with exacerbations of chronic bronchitis. For example, in 120 children with recurrent respiratory infections, pidotimod reduced relapse by 35%, hospitalization by 86% and antibiotic use by 47% compared to placebo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
NACHT, LRR and PYD domains-containing protein 12 1 Target ID: P59046 Gene ID: 91662.0 Gene Symbol: NLRP12 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25620184	Activator 1430
Toll-like receptor 2 1 Target ID: CHEMBL4163 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23663325	Activator 1430
Interleukin-2 receptor alpha chain 1 Target ID: CHEMBL1778 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7857357	Activator 1430
natural killer cell mediated cytotoxicity 1 Target ID: GO:0042267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1294620	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Respiratory tract infections 85 Sources: http://www.mims.com/india/drug/info/pidotimod?mtype=generic	Primary		Approved 8429	Pidotimod Approved Use Pidotimod is an immunostimulant used in patients with cell-mediated immunodepression during respiratory and urinary tract infections.
Urinary tract infections 205 Sources: http://www.mims.com/india/drug/info/pidotimod?mtype=generic	Primary		Approved 8429	Pidotimod Approved Use Pidotimod is an immunostimulant used in patients with cell-mediated immunodepression during respiratory and urinary tract infections.

PubMed

Title	Date	PubMed
Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections.	2002 Aug	12131867
[Therapy with cytokines and thymic factors in a complicated case of common variable immunodeficiency].	2003 Sep-Oct	14631592
Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children.	2004	15260461
[Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico].	2005 Jan-Feb	15957470
Urinary tract infection in children.	2005 Jun	16135271
Synergistic immunostimulatory effect of pidotimod and red ginseng acidic polysaccharide on humoral immunity of immunosuppressed mice.	2008 Dec	19177908
Henoch-Schönlein purpura associated with pidotimod therapy.	2008 May-Jun	18799074
Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression.	2008 Sep	18806958
Pidotimod: a reappraisal.	2009 Apr-Jun	19505378
High-performance liquid chromatography-tandem mass spectrometry for the determination of pidotimod in human plasma and its application to a pharmacokinetic study.	2009 Aug 15	19604731
Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.	2009 Nov	19712757
Complementary treatment with oral pidotimod plus vitamin C after laser vaporization for female genital warts: a prospective study.	2010 Jul-Sep	20945819

Patents

Sample Use Guides

In Vivo Use Guide

Take this medication by mouth, usually 2 to 3 times daily with a full glass of water (8 ounces or 240 milliliters) or as directed by your doctor. Do not lie down for at least 10 minutes after taking this drug.

Route of Administration: Oral

In Vitro Use Guide

Pidotimod 10 and 100 ug/ml increased TLR-2 expression in BEAS-2B cell line (human bronchial epithelial cells infected with a replication-defective Adenovirus 12-SV40 virus hybrid)

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:44:24 UTC 2023` Edited by `admin` on `Sat Dec 16 17:44:24 UTC 2023`
Record UNII	785363R681
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIDOTIMOD

Official Name

English

Pidotimod [WHO-DD]

Common Name

English

(R)-3-((S)-5-OXOPROLYL)-4-THIAZOLIDINECARBOXYLIC ACID

Systematic Name

English

NSC-759841

Code

English

PIDOTIMOD [MART.]

Common Name

English

PIDOTIMOD [MI]

Common Name

English

pidotimod [INN]

Common Name

English

PILIMOD

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QL03AX05